Group 1 - Apollo Hospitals Enterprise (AHEL) plans to acquire International Finance Corporation's (IFC) 31% equity stake in Apollo Health and Lifestyle (AHLL) for Rs12.54bn ($142m), making AHLL a wholly owned subsidiary [1][2] - The acquisition involves purchasing a 30.58% equity stake held by IFC and IFC EAF Apollo Investment Company, resulting in Apollo holding a 99.42% share post-acquisition [2] - AHLL operates multispecialty clinics under the Apollo Clinics brand, providing services such as diabetes management, diagnostics, and planned surgery [3] Group 2 - In FY24/25, AHLL reported a turnover of Rs15.53bn, an increase from Rs13.65bn the previous year [3] - The acquisition aims to sharpen business focus across Apollo's four verticals, enabling AHLL to scale effectively and innovate faster [4] - Apollo Hospitals announced a new 100-bed oncology center with a Rs5.73bn investment, which will include proton therapy as part of its expansion [4][5] Group 3 - This new oncology center marks Apollo's third proton therapy installation in India, with plans to double its oncology business to over Rs50bn within three to four years [5] - The introduction of next-generation proton therapy is seen as a significant advancement in personalized and effective cancer treatment [6] - Apollo Hospitals is collaborating with Ainnova Tech to integrate AI into disease detection and prediction [6]